Healthcare / Medical DevicesParis
$0.51
-0.02 (-4.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-11.0M · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$37M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-97.9%
↓Gross Margin
63.0%
↑Debt/Equity
0.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.6%
FCF CAGR
—
FCF margin
-49.4%
FCF / Net income
0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.0M · net income $-22.9M · FCF $-9.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $20.0M | $20.0M | $19.6M | $10.6M | $21.0M |
| Net Income | $-22.9M | $-22.9M | $-41.8M | $-28.3M | $-25.7M |
| EBITDA | $-8.2M | $-8.2M | $-31.4M | $-12.4M | $-11.7M |
| EPS | -0.32 | -0.32 | -0.59 | -0.40 | -0.36 |
| Gross Margin | 63.0% | 63.0% | 163.4% | 32.9% | 27.3% |
| Operating Margin | -61.8% | -61.8% | 17.1% | -149.0% | -74.5% |
| Net Margin | -114.2% | -114.2% | -212.7% | -266.4% | -122.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.45 | 0.45 | 0.25 | 0.16 | 0.01 |
| Current Ratio | 4.75 | 4.75 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.9M | $-9.9M | $-11.0M | $-23.0M | $-14.1M |
| Returns | |||||
| ROE | -97.9% | -97.9% | -87.2% | -32.4% | -22.3% |
| Valuation | |||||
| P/B | 1.53 | 1.53 | 0.99 | 0.54 | 0.63 |
| Growth & Yield | |||||
| Revenue Growth | 2.0% | 2.0% | 84.8% | -49.5% | — |
| EPS Growth | 45.8% | 45.8% | -47.5% | -11.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.59 → -0.32
Residual
-8.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.